Shionogi & Co., Ltd. Unsponsored ADR (OTCMKTS:SGIOY) Sees Strong Trading Volume Following Strong Earnings

Shionogi & Co., Ltd. Unsponsored ADR (OTCMKTS:SGIOY) saw an uptick in trading volume on Wednesday following a better than expected earnings announcement. 120,666 shares were traded during mid-day trading, an increase of 7% from the previous session’s volume of 112,588 shares.The stock last traded at $9.35 and had previously closed at $8.79.

The company reported $0.18 earnings per share for the quarter, beating analysts’ consensus estimates of $0.15 by $0.03. Shionogi & Co., Ltd. Unsponsored ADR had a net margin of 41.82% and a return on equity of 13.70%. The firm had revenue of $881.71 million for the quarter, compared to analysts’ expectations of $895.52 million.

Analyst Upgrades and Downgrades

Several equities analysts recently weighed in on the stock. The Goldman Sachs Group upgraded shares of Shionogi & Co., Ltd. Unsponsored ADR to a “hold” rating in a report on Wednesday, April 8th. Zacks Research downgraded Shionogi & Co., Ltd. Unsponsored ADR from a “hold” rating to a “strong sell” rating in a report on Thursday, April 16th. One research analyst has rated the stock with a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Reduce”.

Shionogi & Co., Ltd. Unsponsored ADR Stock Performance

The firm has a market capitalization of $15.90 billion, a PE ratio of 12.29, a price-to-earnings-growth ratio of 0.75 and a beta of 0.10. The company has a debt-to-equity ratio of 0.01, a current ratio of 5.84 and a quick ratio of 5.21. The stock has a 50-day moving average price of $10.51 and a 200-day moving average price of $9.77.

Shionogi & Co., Ltd. Unsponsored ADR Company Profile

Shionogi & Co, Ltd. is a Japan-based pharmaceutical company that conducts research, development, manufacturing and marketing of prescription drugs and vaccines. Established in the late 19th century, the company has expanded its focus beyond domestic markets to become a global player in pharmaceuticals, with particular expertise in anti-infectives, pain management, cardiovascular and central nervous system disorders.

The company’s product portfolio spans both established and innovative therapies.